Dan Stanton

When potential customers would not risk their molecules on an unproven continuous manufacturing line, Enzene Biosciences proved the point itself, developing and launching four of its own biosimilars on the platform.

Collapsing entry prices and a thickening field of competitors have recast process intensification for biosimilars as a question of commercial survival through speed and agility.